Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-14T23:15:52.164Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychosis in Parkinson’s disease: a clinical biomarker of disease stage and prognosis

Published online by Cambridge University Press:  19 July 2023

M. Pinho ,
D. O. Martins ,
P. S. Martins ,
L. Gomes  and
S. Carvalho
M. Pinho*
Affiliation:
Hospital de Magalhães Lemos, Porto, Portugal
D. O. Martins
Affiliation:
Hospital de Magalhães Lemos, Porto, Portugal
P. S. Martins
Affiliation:
Hospital de Magalhães Lemos, Porto, Portugal
L. Gomes
Affiliation:
Hospital de Magalhães Lemos, Porto, Portugal
S. Carvalho
Affiliation:
Hospital de Magalhães Lemos, Porto, Portugal
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor and nonmotor symptoms, the latter contributing significantly to morbidity, mortality, nursing home placement and quality of life.

Objectives

We present a literature review about the impact of psychosis on PD’s prognosis.

Methods

A literature review is performed on PUBMED, using the next keywords: "Parkinson’s disease”, “psychosis” and “prognosis”. We focused on data from systematic reviews, clinical trials and meta-analysis published in English on last 10 years.

Results

Psychosis is a common feature of Parkinson’s disease, occurring in up to 30% of PD patients treated chronically with antiparkinsonian drugs. Visual hallucinations are the most common psychotic symptom observed, delusions being considerably less common and affecting only 5% of treated patients.

Positive symptoms in PD vary across its course: early in the disease, passage hallucinations, illusions and presence hallucinations occur; later, complete visual hallucinations, initially with good insight, then without insight.

Psychosis spectrum symptoms in early PD predict a decline in cognitive function at 2 years, especially visual hallucinations. There is an association between visual hallucinations and the subsequent emergence of dementia.

Conclusions

Current evidence highlights the role of PD psychosis as a clinical biomarker of disease stage, distribution and future progression. Early recognition and treatment of psychotic symptoms improves disease’s outcomes.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S938
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.